Resulting in the advancement of treatment Of Cystic Fibrosis
LOS ANGELES, Nov. 27 /PRNewswire/ -- It is impossible to over estimate the effect Dr. Francis S. Collins' work has had on public health. Fifty years ago, children living with cystic fibrosis (CF) would not have been expected to live past their early teens. Thanks to the research work of Dr. Collins, and the subsequent advancement in treatment, people can now expect to live into their thirties, forties and beyond.
It is in recognition of his extraordinary work on the CF gene and identification of the human genome, that the Will Rogers Institute (WRI) will honor Dr. Collins with the inaugural "Annual Prize for Outstanding Contributions to Lung Research." The award will be presented on Thursday, December 6, 2007 at the WRI Board of Directors Meeting at the Beverly Hills Hotel.
Dr. Collins' seminal research led to the identification of the CF gene and its protein product, CFTR. Mutation of the gene results in CF, a chronic disease which attacks the lungs and other organs. It is estimated that 30,000 children and adults in the United States struggle with cystic fibrosis. More than 10 million Americans are unknowing, symptom-free carriers of the disease, which can only be identified by genetic testing.
His work has proved to be a motivator for advancements in many other genetic investigations including type 2 diabetes, neurofibromatosis and Huntington's disease.
Dr. Edward Crandall, PhD, MD, medical advisor to the Will Rogers
Institute and Hastings Professor and Norris Chair of Medicine at the
University of Southern California (USC), stated, "Dr. Collins was chosen by
the WRI as the first recipient of the prize because his work has
consistently produced outstanding and influential research that has been
published in the foremost peer-review journals. He maintains a very
important leadership role in his field, and is held in the highest esteem
by scientists and clinic
|SOURCE Will Rogers Institute|
Copyright©2007 PR Newswire.
All rights reserved